| Date | Title | Description |
| 27.07.2026 | Labcorp Launches Marker Genetic Health Panel on Labcorp OnDemand for 100+ Actionable Conditions | What You Should Know
Labcorp has unveiled the Marker by Labcorp™ Genetic Health Panel, an integrated consumer offering evaluating 163 genes associated with over 100 medically actionable hereditary conditions (including cancer, cardiovascula... |
| 12.05.2026 | Labcorp Integrates Full Diagnostic Menu into Epic Aura: Streamlining Lab Workflows for U.S. Health Systems | What You Should Know
Labcorp and Epic have announced an expanded collaboration to make Labcorp’s full diagnostic test menu available through Epic’s Aura platform.
The integration allows clinicians to order tests and receive discrete results... |
| 25.09.2025 | UberDoc Appoints Sean Kearney as CEO to Drive Next Phase of Growth and Innovation | UberDoc
New leadership to drive rapid growth as patients demand speed, transparency, and control in healthcare access.
BOSTON, Sept. 25, 2025 /PRNewswire-PRWeb/ -- UberDoc, an innovative healthcare platform empowering patients to connect wi... |
| 15.08.2025 | Citizen Health Secures $30M: A New Era for Rare Disease Care | Citizen Health secures $30M Series A, reaching $44M total. This patient-powered platform transforms rare disease care. It integrates AI, community support, and health data. Patients gain control over complex conditions. Funds will expand op... |
| 15.08.2025 | Citizen Health: $30 Million Secured For Patient-Powered Platform Transforming Rare Disease Care | Citizen Health, a patient-driven platform redefining care for rare diseases, announced it has secured $30 million in Series A financing. This round was led by 8VC with support from Transformation Capital and Headline, bringing total funding... |
| 19.12.2024 | Colorado BioScience Association: Life Sciences Ecosystem Raised $2.15 Billion This Year | The Colorado BioScience Association (CBSA) announced that the state’s life sciences ecosystem raised $2.15 billion in 2024, a 46% increase compared to 2023. Colorado – recognized as the Hub for Health Impact – has brought in nearly $12 bill... |
| 20.11.2024 | Genetic Testing Delivers Startup Hits And Misses | 3 Shares Email Facebook Twitter LinkedIn
When submitting a genetic test, one usually has a desired outcome in mind. That doesn’t mean the results will bear it out.
Investing in DNA testing startups is much the same. Over the years, startup ... |
| 03.04.2024 | SoftBank's View files for bankruptcy 3 years after its SPAC. Here's how it went from investor darling to problem child. | Premium Finance SoftBank's View files for bankruptcy 3 years after its SPAC. Here's how it went from investor darling to problem child.
Hayley Cuccinello
2024-04-03T17:10:54Z
Share icon An curved arrow pointing right.
Share
Facebook Icon Th... |
| 13.03.2024 | Prognos Health and Invitae Partner to Improve Diagnosis and Advance Novel Treatments for Rare, Genetic-Driven Disease | Prognos Health, the most-trusted provider of real-world data, and Invitae, a leading medical genetics company, today announced a strategic partnership.
This powerful synergy will empower researchers, clinicians, and patients in unprecedente... |
| 23.01.2024 | Invitae Sells Reproductive Health Assets to Natera for Up to $52.5M | What You Should Know:
– Invitae (NYSE: NVTA), a medical genetics company, announced the completion of its sale of certain reproductive health assets, including carrier screening and non-invasive prenatal screening (NIPS), to Natera (NASDAQ:... |
| 15.03.2023 | Invitae to Present Data at The American Clinical Genetics Meeting 2023 That Supports Removing Barriers to Genetic Testing | – New research looking at underrepresented racial, ethnic and ancestry groups underscores the importance of universal germline genetic testing –
SAN FRANCISCO, March 15, 2023 /PRNewswire/ -- Invitae NVTA, a leading medical genetics company,... |
| 28.02.2023 | Invitae Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Company Updates | – Entered into a ~$336 million transaction for the 2024 convertible notes, effectively addressing ~96% of the amount outstanding (see separate press release to follow) –
– Repaid its 2024 senior secured term loan in full, improving its bala... |
| 01.08.2022 | Slone Partners Places Thomas Schlumpberger as Chief Executive Officer at Nanomix | “Thomas Schlumpberger is an experienced and admired leader in the POC diagnostics field where he has achieved extraordinary success in every management role,” said Slone Partners President Tara Kochis.
SOUTH RIDING, Va. (PRWEB) August 01, 2... |
| 01.08.2022 | Eight Business Leaders Share Their Takes On Unhelpful Productivity ‘Advice’ | There’s a lot of great business advice out there—but there’s also an equal amount of unhelpful advice. While many people think they have the answers, only you can know what’s right for your business. However, it can sometimes be hard for ne... |
| 16.06.2022 | Eight Steps A Leader Should Take When Faced With A Company Crisis | There are many crises that a company can face during its lifetime, and they happen for many different reasons. Whether it's a financial crisis, an economic crisis, an environmental crisis or any other type of crisis, it's important for busi... |
| 08.06.2022 | Employees Quitting Due To Bad Leadership? Nine Ways To Fix It | As the Great Resignation continues, one in five employees say they are planning to switch jobs in the next year. Experts have cited a few reasons why so many people are making the switch since the start of the pandemic, with one of those re... |
| 30.03.2022 | Invitae Launches Genomics-Forward Digital Health Platform | What You Should Know:
– Invitae launches a seamless digital platform to enhance patient and provider experiences and further bring genetics to mainstream medicine.
– Offering seamless integrations with EHR solutions, Invitae Digital Health ... |
| 07.03.2022 | KCNT1 Epilepsy Foundation Launches Digital Natural History Study in Partnership with Invitae Ciitizen | CONTOOCOOK, N.H. (PRWEB) March 07, 2022
The KCNT1 Epilepsy Foundation today announced in partnership with Invitae, the launch of its Digital Natural History Study (NHS) using Invitae’s Ciitizen technology, a patient-mediated platform that a... |
| 10.01.2022 | Invitae Reports Preliminary 2021 Revenue of More Than $458 Million and Billable Volume of More Than 1.16 Million | SAN FRANCISCO, Jan. 10, 2022 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, announced preliminary unaudited full-year 2021 revenue, billable volume and commercial metrics reporting approximately 64 per... |
| 09.11.2021 | Invitae Reports $114.4 Million in Revenue Driven by 296,000 in Billable Volume in Third Quarter of 2021 | SAN FRANCISCO, Nov. 8, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the third quarter ended September 30, 2021.
"Year-over-year growth continued at a... |
| 09.11.2021 | Invitae Reports $114.4 Million In Revenue Driven By 296,000 In Billable Volume In Third Quarter Of 2021 | — Q3 2021 revenue increases more than 66% on volume growth of 89% from Q3 2020 — — Full-year 2021 revenue expected to grow 60-70%, or between $450-$475 million — — Hosting conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p... |
| 22.10.2021 | Invitae : UCL and the Francis Crick Institute Announce New Data From TRACERx Research Collaboration at the 2021 International Society of Liquid Biopsy Congress | SAN FRANCISCO, Oct. 22, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), University College London (UCL), and the Francis Crick Institute today announced new data from their TRACERx lung cancer research collaboration funded by Cancer Research UK ... |
| 07.09.2021 |
Wavemaker Three-Sixty Health Gets Exit At Ciitizen
| Los Angeles-based healthcare venture capital investor Wavemaker Three-Sixty Health has scored an exit in its portfolio, through the acquisition of Ciitizen by Invitae. According to Wavemaker Health, Ciitizen was its third investment in its ... |
| 07.09.2021 | Invitae : to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research | SAN FRANCISCO, Sept. 7, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Ciitizen, a patient-centric consumer health tech company. Backed by... |
| 07.09.2021 | Genetic testing company Invitae snaps up digital health record company Ciitizen for $325M | Photo: FatCamera/Getty Images |
| 07.09.2021 | Invitae to Acquire Ciitizen to Strengthen its Patient-Consented Health Data Platform to Improve Personal Outcomes and Global Research | |
| 09.07.2021 | Invitae Acquires Ciitizen for $325M to Strengthen its Patient-Consented Health Data Platform | What You Should Know:
– Medical genetics company Invitae today announced its $325M acquisition of Ciitizen, a patient-centric consumer health tech company that offers a global platform to help patients collect, organize, store and share the... |
| 17.06.2021 | How companies like 23andMe and Helix are forging the future of consumer genomics despite a bottomed out market | 23andMe cofounder Anne Wojcicki. Kimberly White / Getty Images This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
23andMe in June started trading after going public in a deal that valued the... |
| 11.06.2021 | Invitae appoints technology and medtech veteran Roxi Wen as chief financial officer | |
| 11.06.2021 | INVITAE CORPORATION
Invitae : appoints technology and medtech veteran Roxi Wen as chief financial officer | SAN FRANCISCO, June 11, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Roxi Wen as its chief financial officer, effective June 21, 2021. Wen brings decades of success as a s... |
| 14.05.2021 | Prevent Blindness Declares Second Annual Inherited Retinal Disease (IRD) Genetic Testing Week as May 16-22 | Prevent Blindness declares May 16-22, 2021, as it's second annual “Inherited Retinal Disease (IRD) Genetic Testing Week” “By encouraging the public to educate themselves about IRDs and the positive impact that genetic testing may have on th... |
| 15.04.2021 | Study finds risk-causing genetic changes in nearly 1 in 6 patients with colorectal cancer | |
| 06.04.2021 | Invitae surges after report says Softbank will lead a $1.2 billion investment in the genetic-testing company | The genetic testing company Invitae is set to receive a $1.2 billion investment led by Softbank.
Invitae also announced it will acquire a genomics company, Genosity, in a $200 million deal.
The firm turned in revenues of $280 million and a ... |
| 05.04.2021 | INVITAE CORPORATION
Invitae : Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives | SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced that a small group of investors, led by SB Management, a subsidiary of Softbank Group Corp., will make an investment of $... |
| 05.04.2021 | Invitae to acquire Genosity to accelerate access to personalized oncology testing worldwide | |
| 05.04.2021 | Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives | |
| 05.04.2021 | INVITAE CORPORATION
Invitae : to acquire Genosity to accelerate access to personalized oncology testing worldwide | SAN FRANCISCO, April 5, 2021 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced it has entered into a definitive agreement to acquire Genosity Inc. ("Genosity"), a genomics company offering i... |
| 11.03.2021 | Invitae Releases Inaugural Environmental, Social and Governance (ESG) Report | SAN FRANCISCO, March 11, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the issuance of its inaugural Environmental, Social and Governance (ESG) report, augmenting the company's di... |
| 23.02.2021 | Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians | SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced expanded capabilities that enable clinicians to use its advanced clinical chatbot Gia to guide their patients... |
| 23.02.2021 | Invitae expands capabilities of its advanced clinical chatbot Gia, enhancing telemedicine support for patients and clinicians | |
| 10.02.2021 | Gene screenings hold disease clues, but unexplained anomalies often raise fears | Tran knew she had an elevated risk of developing breast cancer because of her family history — her mother died of the disease and a maternal aunt was diagnosed and survived. Given this, she planned to follow the standard recommendations to ... |
| 21.01.2021 | Invitae Announces Pricing of Public Offering of Common Stock | |
| 20.01.2021 | Invitae Announces Proposed Public Offering of Common Stock | |
| 17.12.2020 | Invitae Introduces Routine Exome Reanalysis to Help Patients Receive Diagnoses Faster | |
| 19.11.2020 | New Study Highlights the Importance of Genetic Testing for Pancreatic Cancer Patients | |
| 08.10.2020 | Invitae : New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing | SAN FRANCISCO, Oct. 8, 2020 /PRNewswire/ -- Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germline genetic tests identify, according to a new study published this week in JAMA Network Ope... |
| 08.10.2020 | New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing | |
| 05.10.2020 | Invitae closes $1.4B acquisition of Boulder’s ArcherDX | Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold.
In a statement Monday, Invitae said... |
| 05.08.2020 | INVITAE CORPORATION
Invitae : Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020 | SAN FRANCISCO, Aug. 4, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2020.
"While we experienced signifi... |
| 06.12.2019 | Analysis: November 2019 Health IT M&A Activity, Public Company Performance | – Healthcare Growth Partners’ (HGP) summary of Health IT/digital health mergers & acquisition (M&A) activity, and public company performance during the month of November 2019
We did a doubletake when we noticed all of the HGP health... |
| 07.11.2019 | Vermont Health Network Launches Pilot Project to Offer Free Genetic DNA Testing | Key Highlights
LunaPBC announces a partnership allowing patients in Vermont to donate genetic information to medical research via a partnership with the University of Vermont Health Network via Invitae.
Free genetic testing is now offered t... |
| 20.06.2019 | Invitae Acquires Singular Bio, for $55M | Invitae Corporation (NASDAQ: NVTA), a San Francisco, CA-based medical genetics company, is to acquire Singular Bio, Inc., a company developing single molecule detection technology that enables lower costs and expanded use of cell-free, nucl... |
| 28.09.2017 | Charting the growth in the reproductive health genetic testing market | But now there has been progress in different methods of reproductive genetic testing. For instance, a recent explosion of the utilization of additional non-invasive prenatal testing (NIPT), and the continuous expansion of upstream preconcep... |
| 31.07.2017 | Safeguard Scientifics Partner Company Good Start Genetics To Be Acquired By Invitae Corporation | Safeguard Scientifics, Inc. (NYSE:SFE) today announced that its partner company, Good Start Genetics, Inc., signed a definitive agreement to be acquired by San Francisco-based genetics information company, Invitae Corporation (NYSE:NVTA). T... |
| 26.07.2017 | The second coming of consumer genomics with 3 predictions for 2018 | A brief history of human genomics
Genomics is defined by the WHO as the study of all parts of an organism’s genes and their functions whereas genetics is the study of heredity or how single genes are passed between generations. The Human Ge... |
| 25.05.2017 | Can telehealth solve America’s genetic counselor shortage? | The trouble is, there aren’t that many trained genetic counselors out there. Lisa Alderson, cofounder and CEO of Genome Medical, puts the numbers at around 4,000 nationwide with an additional 2,500 geneticists who can make scientific sense ... |
| 28.10.2016 | Digital health deals: Vocera buys Extension, Red Cross-Teladoc and more | San Jose-based Vocera Communications, which offers communications services for hospitals and health systems, has acquired fellow clinical communications company Extension Healthcare for $55 million in an all-cash transaction.The acquisition... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appetite for R&D risk | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. But from 2013 through 2015 generalist investors got over their fears and jumped into one of the hottest stock games on the planet. Fund... |
| 29.03.2016 | Invitae expanding gene panels well beyond cancer | Genetic testing panels, more often than not, tend to focus these days on cancer. San Francisco’s Invitae is expanding its genetic testing panels past oncology into neurology, pediatrics and rare diseases – as well as new screening for newbo... |
| 27.03.2015 | Genomics Needs A Killer App | Mark Kaganovich Contributor
Mark Kaganovich is the CEO and cofounder of SolveBio . Follow him on twitter at @markkaganovich.
More posts by this contributor
Is enterprise genomics good enough yet?
Genomics is an incredible technology for new... |
| 27.03.2015 | New digital health investment fund rises | In a phone interview with MedCity News, Kendall said the average size of investments it will make will range from $250,000 to $1.5 million.
“As a rule of thumb we will stick with companies that are really young. It’s a rule of thumb so it’s... |
| 02.02.2015 | OrbiMed draws in more healthcare strategics in nearly $1 billion royalty and credit fund | A dozen leading medical research and healthcare institutions contributed to the royalty and credit fund – the most ever, Managing Director Tadd Wessel said. He wouldn’t say how much these strategic partners contributed, but added OrbiMed wa... |
| 17.01.2015 | The biggest healthtech deals of 2014 | Categories include telemedicine, digital medical devices and personalized medicine
This month, in anticipation of Vator hosting its first ever Splash Health event on February 12th, we've been putting the spotlight on the healthtech space.
E... |
| 13.01.2015 | The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped) | “It’s just that sequencing isn’t good enough today for many of the applications we’re looking at for future clinical use,” he said.
Stuelpnagel, who now chairs Ariosa Diagnostics, 10X Genomics and the just-acquired Sequenta, spoke this week... |
| 09.01.2015 | Genetics testing company Invitae files for an initial public offering | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
The San Francisco-based genetics company Invitae ... |
| 13.10.2014 | Invitae Completes $120M Series F Round |
SAN FRANCISCO, CA, Genetic information company, today announced the completion of a $120 million Series F financing.
>> Click here for more funding data on Invitae
>> To export Invitae funding data to PDF and Excel, click he... |
| 13.10.2014 | Genetic information player Invitae raises $120M for global expansion | Promoted
This Patient Experience Checklist Is Your Key To Success in 2021
As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| 13.10.2014 | Invitae raises $120M for its $1,500 gene sequencing test | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
Genomics will someday be your doctor’s major weap... |
| 13.10.2014 | Invitae raises $120M for its $1,500 gene sequencing test | Genomics will someday be your doctor’s major weapon for keeping you healthy throughout your life.
The San Francisco-based genetics company Invitae is pushing hard toward making that a reality. The company has developed a test that sequences... |
| 13.10.2014 | Invitae Completed $120M Series F Financing | Invitae Corporation, a San Francisco, CA-based genetic information company, completed a $120m Series F financing.
Backers included new investors The Broe Group, Decheng Capital, Deerfield Management LLC, OrbiMed, Perceptive Advisors, Rock S... |
| 11.12.2013 | Invitae Completes $40M Series E Financing | Invitae Corporation, a San Francisco, CA-based genetic diagnostics company, completed a $40m Series E financing.
Backers included Genomic Health, Inc. (NASDAQ: GHDX), Randy Scott, Thomas McNerney & Partners, Redmile Group, Genesys Capit... |
| 22.01.2013 | Genomics startup gets $3M to usher in new era of ‘personalized medicine’ | We are excited to bring Transform 2022 back in-person July 19 and virtually July 20 - 28. Join AI and data leaders for insightful talks and exciting networking opportunities. Register today!
The cost of sequencing the human genome has plumm... |
| 22.01.2013 | Syapse Raises $3M From The Social+Capital Partnership To Bring Genomic Information To Everyday Healthcare | Founded at Stanford University in 2008, Syapse has been on a mission to help disrupt healthcare by incorporating “omics” (or the study of fields within biology typically ending in “-omics,” like genomics, proteomics or metabolomics, for exa... |
| 22.01.2013 | Genomics startup gets $3M to usher in new era of ‘personalized medicine’ | The cost of sequencing the human genome has plummeted. But how will this benefit doctors and patients?
Biomedical researchers hope to harness data about the human gene pool to usher a new era of “personalized medicine,” which could lead to ... |
| - | Gene screenings hold disease clues, but unexplained anomalies often raise fears | When her gynecologist recommended genetic testing, Mai Tran was reluctant.
“I didn’t really want to do it,” recalled Tran, who had just turned 21 and was living in New York City, “but she kept on emailing me about it and was really adamant ... |
| - | The second coming of consumer genomics with 3 predictions for 2018 | As healthcare venture investors, my colleagues Adam Seabrook, Hailey Hu, and I identify disruptive trends at the intersection of healthcare and technology and back companies that are pursuing those trends. Occasionally, albeit rarely, we co... |
| - | OrbiMed draws in more healthcare strategics in nearly $1 billion royalty and credit fund | Healthcare investor OrbiMed announced its second debt and royalty fund on Monday and continued to expand efforts to add more healthcare institutions as investors.
The $924 million OrbiMed Royalty Opportunities II will invest between $20 mil... |
| - | Genetic information player Invitae raises $120M for global expansion | Gene diagnostics megaplayer Invitae has raised a whopping $120 million in a Series F round – proof positive that startups operating in the vein of 23andMe are able to attract large swaths of cash. The company has a single diagnostic test th... |
| - | Cathie Wood called this one of her most underappreciated stocks. Its CEO explains its growth story | Ark Invest’s Cathie Wood called Invitae one of her most underappreciated holdings.
The CEO of the genetic testing company told CNBC on Friday it has grand visions to improve health-care outcomes.
“We are relentlessly pursuing the idea of ge... |
| - | Can telehealth solve America’s genetic counselor shortage? | Humans on average carry 1-2 mutations that could cause severe genetic disorders for them or their offspring. But what does that really mean?
It means something different for every person that finds out. Which is why genetic counselors are s... |
| - | Charting the growth in the reproductive health genetic testing market | The reproductive genetic testing market is poised for substantial investment and growth as demand continues, reimbursement improves, and the technology expands to additional, novel applications.
The market has historically been dominated by... |
| - | A diagnostic odyssey: spotting the zebras among the horses | By Michele Cunningham
While individually rare, collectively there are more than 7,000 rare diseases that affect nearly 30 million people in the U.S.[i] Their symptoms and disabilities may vary, but the stories they tell, share many commonal... |
| - | Как американская компания Invitae построила корпоративную культуру с тонким балансом свободы и ответственности... | Как американская компания Invitae построила корпоративную культуру с тонким балансом свободы и ответственности
30 Июня, 2017, 15:00
Ольга Дьякова
11535
Эффективная корпоративная культура — один из решающих факторов долгосрочного успеха бизн... |
| - | The future of next-gen sequencing (and why an Illumina cofounder’s never had his genome mapped) | John Stuelpnagel – one of Illumina‘s cofounders – has never had his genome sequenced.
“I didn’t feel the need,” Stuelpnagel said.
It’s not because of the cost, nor the fear he’s got some genetic disorder. It’s not even because he believes i... |
| - | Genetic insights can enhance hereditary cancer risk and care management. How can we expand adoption? | The multifactorial and heterogeneous nature of cancer makes it challenging to develop treatment plans that meet the unique needs of every patient. A genetics-informed, personalized care plan empowers patient-specific risk management and pot... |
| - | Invitae to Present at the Oppenheimer 31st Annual Healthcare Conference | SAN FRANCISCO, March 4, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will present at the Oppenheimer 31st Annual Healthcare Conference on Tues... |
| - | Invitae expanding gene panels well beyond cancer | Genetic testing panels, more often than not, tend to focus these days on cancer. San Francisco’s Invitae is expanding its genetic testing panels past oncology into neurology, pediatrics and rare diseases – as well as new screening for newbo... |
| - | Invitae adds Medneon's risk assessment tools to its education and clinical support offerings | SAN FRANCISCO, Feb. 24, 2021 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the addition of tools from Medneon, a digital health AI company, to its robust clinical workflow and patient ... |
| - | New digital health investment fund rises | In what feels like a counterweight to the ongoing discussion of the relatively few women partners in venture capital, a new digital health investment firm has raised a $10.7 million fund. It’s led by angel investor Enmi Sung Kendall and Any... |
